Environmental neurotoxin-induced progressive model of parkinsonism in rats

Annals of Neurology

Volumn 68, Issue 1, 2010, Pages 70-80

  Shen, Wei Bin ^a   McDowell, Kimberly A ^a   Siebert, Aubrey A ^a   Clark, Sarah M ^a   Dugger, Natalie V ^b   Valentino, Kimberly M ^b   Jinnah, H A ^c   Sztalryd, Carole ^a   Fishman, Paul S ^a,b   Shaw, Christopher A ^d   Jafri, M Samir ^a,b   Yarowsky, Paul J ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; UBIQUITIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CINGULATE GYRUS; CONTROLLED STUDY; CORPUS STRIATUM; CYCAS; CYCAS MICRONESICA; DISEASE COURSE; DOPAMINERGIC NERVE CELL; FLOUR; HISTOPATHOLOGY; IN VITRO STUDY; LOCUS CERULEUS; MALE; MOTOR DYSFUNCTION; NERVE DEGENERATION; NEURITE; NEUROTOXICITY; NONHUMAN; PARKINSONISM; PHENOTYPE; PLANT SEED; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ANIMALS; BRAIN; CYCAS; DIET; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DYSKINESIAS; FLOUR; MALE; NERVE DEGENERATION; NEURONS; NEUROTOXINS; PARKINSONIAN DISORDERS; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD;

EID: 77954073901     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22018     Document Type: Article

References (46)

1. Thomas B, Beal MF. Parkinson's disease. Hum Mol Genet 2007;16 Spec No. 2:R183-R194.
2. Hornykiewicz O. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness. Neurodegener Dis 2008;5:114-117. (Pubitemid 351347826)
3. Perl DP. The neuropathology of parkinsonism. In: Handbook of clinical neurology. Vol 83. Parkinson's disease and related disorders. Part I. Philadelphia, PA: Elsevier, 2007. pp. 205-215.
4. Morris HR, Steele JC, Crook R, et al. Genome-wide analysis of the parkinsonism-dementia complex of Guam. Arch Neurol 2004; 61:1889-1897.
5. Uversky VN. Neurotoxicant-induced models of Parkinson's disease: understanding the role of rotenone, maneb, and paraquat in neurodegeneration. Cell Tissue Res 2004;318:225-241.
6. Ince PG, Codd GA. Return of the cycad hypothesis - does the amyotrophic lateral sclerosis/parkinsonism dementia complex (ALS/PDC) of Guam have new implications for global health? Neuropathol Appl Neurobiol 2005;31:345-353.
7. Kurland LT. Amyotrophic lateral sclerosis and Parkinson's disease complex on Guam linked to an environmental neurotoxin. Trends Neurosci 1988;11:51-54.
8. Hirano A, Kurland LT, Krooth RS, et al. Parkinsonism-dementia complex, an endemic disease on the island of Guam: 1. Clinical features. Brain 1961;84:642-661.
9. Plato CC, Garruto RM, Galasko D, et al. Amyotrophic lateral sclerosis and parkinsonism-dementia complex of Guam: changing incidence rates during the past 60 years. Am J Epidemiol 2003; 157:149-157. (Pubitemid 36077446)
10. Borenstein AR, Mortimer JA, Schofield E, et al. Cycad exposure and risk of dementia, MCI, and PDC in the Chamorro population of Guam. Neurology 2007;68:1764-1771.
11. Hirano A, Malamud N, Kurland LT. Parkinsonism-dementia complex, an endemic disease on the island of Guam: II. Pathological features. Brain 1961;84:662-679.
12. Marler TE, Lee V, Shaw CA. Cycad toxins and neurological diseases in Guam: defining theoretical and experimental standards for correlating human disease with environmental toxins. Hort- Science 2005;40:1598-1605. (Pubitemid 41318302)
13. Howland DS, Liu J, She Y, et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci U S A 2002;99:1604-1609.
14. Wilson JM, Khabazian I, Wong MC, et al. Behavioral and neurological correlates of ALS-parkinsonism dementia complex in adult mice fed washed cycad flour. Neuromusc Med 2002;1: 207-221.
15. Shaw CA, Wilson JMB. Analysis of neurological disease in 4 dimensions. Neurosci Biobehev Rev 2003;27:493-505.
16. Olanow CW, Kordower JH. Modeling Parkinson's disease. Ann Neurol 2009;66:432-436.
17. Khabazian J, Bains JS, Williams DE, et al. Isolation of various forms of sterol beta-d-glucoside from the seed of the Cycas circinalis: neurotoxicity and implications for ALS-parkinsonism dementia complex. J Neurochem 2002;82:516-528.
18. Schwarting RK, Sedelis M, Hofele K, et al. Strain-dependent recovery of open-field behavior and striatal dopamine deficiency in the mouse MPTP model of Parkinson's disease. Neurotox Res 1999;1:41-56.
19. Schallert T, Tillerson JL. Intervention strategies for degeneration of dopamine neurons in parkinsonism: optimizing behavioral assessment of outcome. In: Central nervous system diseases: innovative animal models from lab to clinic. Totowa, NJ: Humana Press, 2000. pp. 131-153.
20. Salamone JD, Mayorga AJ, Trevitt JT, et al. Tremulous jaw movements in rats: a model of parkinsonian tremor. Prog Neurobiol 1998;56:591-611.
21. Wilson JM, Levey AI, Rajput A, et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 1996;47:718-726. (Pubitemid 26307303)
22. Gorbatyuk OS, Shoudong L, Sullivan LF, et al. The phosphorylation state of Ser-129 in human α-synuclein determines neurodegeneration in a rat model of Parkinson's disease. Proc Natl Acad Sci U S A 2008;105:763-769.
23. Siebert AS, Desai V, Chandrasekaran K, et al. Nrf2 activators provide neuroprotection against 6-hydroxydopamine toxicity in rat organotypic nigrostriatal co-cultures. J Neurosci Res 2009;87: 1659-1669.
24. Plenz D, Kitai ST. Organotypic cortex-striatum-mesencephalon cultures: the nigrostriatal pathway. Neurosci Lett 1996;209: 177-180. (Pubitemid 26164954)
25. Lannuzel A, Höglinger GU, Verhaeghe S, et al. Atypical parkinsonism in Guadeloupe: a common risk factor for two closely related phenotypes? Brain 2007;30:816-827.
26. Caparros-Lefebre D, Lees AJ. Atypical unclassificable parkinsonism in Guadeloupe: an environmental toxic hypothesis. Mov Disord 2005;(suppl 12):S114-S118.
27. Fellows SJ, Noth J. Grip force abnormalities in de novo Parkinson's disease. Mov Disord 2004;19:560-565.
28. Traynor BJ, Zhang H, Shefner JM, et al. Functional outcome measures as clinical endpoints in ALS. Neurology 2004;63: 1933-1935. (Pubitemid 39532394)
29. Alerte TNM, Akinfolarin AA, Fredrich EE, et al. α-Synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice. Neurosci Lett 2008;435:24-29.
30. Hashimoto M, Rockenstein E, Crews L, et al. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Neuromolecular Med 2003;4:21-36. (Pubitemid 37315183)
31. Chen L, Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 2005;8:657-663. (Pubitemid 40594208)
32. Jellinger KA. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution - a pilot study. Acta Neuropathol 2003;106:191-201.
33. Braak H, Del Tredici K. Neuroanatomy and pathology of sporadic Parkinson's disease. Adv Anat Embryol Cell Biol 2009;201:1-119.
34. Betarbet R, Greenamyre T. Parkinson's disease: animal models. In: Handbook of clinical neurology. Vol 83. Parkinson's disease and related disorders. Part 1. Philadelphia, PA: Elsevier, 2007. pp. 265-287.
35. Tinsley RB, Bye CR, Parish CL, et al. Dopamine D2 receptor knockout mice develop features of Parkinson disease. Ann Neurol 2009;66:472-484.
36. Chu Y, Kordower JH. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease? Neurobiol Dis 2007;25:134-149.
37. Langston JW, Forno LS, Tetrud J, et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine exposure. Ann Neurol 1999;46:598-605.
38. Chen MK, Kuwabara H, Zhou Y, et al. VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. J Neurochem 2008;105:78-90. (Pubitemid 351441627)
39. Braak H, Del Tredici K, Bratzke H, et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 2002; 249(suppl 3):III/1-5.
40. Braak H, Del Tredici K. Neuroanatomy and pathology of sporadic Parkinson's disease. Adv Anat Embryol Cell Biol 2009;201:1-119.
41. Betarbet R, Sherer TB, MacKenzie G, et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3:1301-1306.
42. Sherer TB, Kim JH, Betarbet R, Greenamyre JT. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 2003;179:9-16. (Pubitemid 36062614)
43. McCormack AL, Mak SK, Shenasa M, et al. Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys. J Neuropathol Exp Neurol 2008;67:793-802.
44. Kim HJ, Fan X, Gabbi C, et al. Liver X receptor beta (LXRbeta): a link between beta-sitosterol and amyotrophic lateral sclerosis- Parkinson's dementia. Proc Natl Acad Sci U S A 2008;105: 2094-2099.
45. Jansen PJ, Lütjohann D, Abildayeva K, et al. Dietary plant sterols accumulate in the brain. Biochim Biophys Acta 2006;1761:445-453.
46. Tabata RC, Wilson JM, Ly P, et al. Chronic exposure to dietary sterol glucosides is neurotoxic to motor neurons and induces an ALS-PDC phenotype. Neuromolecular Med 2008;10:24-39.